Genetically Engineered Animals, 54360-54361 [E8-21977]

Download as PDF 54360 Federal Register / Vol. 73, No. 183 / Friday, September 19, 2008 / Notices OMB Control Number: 0572–0107. Summary of Collection: The Rural Electrification Act of 1936, 7 U.S.C. 901 et seq., as amended, (RE ACT) in Sec. 4 (7 U.S.C. 904) authorizes and empowers the Administrator of the Rural Utilities Service (RUS) to make loans in the several States and Territories of the United States for rural electrification and the furnishing and improving of electric energy to persons in rural areas. These loans are for a term of up to 35 years and are secured by a first mortgage on the borrower’s electric system. In the interest of protecting loan security and accomplishing the statutory objective of a sound program of rural electrification, Section 4 of the RE Act further requires that RUS make or guarantee a loan only if there is reasonable assurance that the loan, together with all outstanding loans and obligations of the borrower, will be repaid in full within the time agreed. RUS will collect information using various RUS forms. Need and Use of the Information: RUS will collect information to implement certain provisions of the RUS standard form of loan documents regarding the borrower’s purchase of materials and equipment and the construction of its electric system by contract or force account. The information will be used by RUS electric borrowers and their contractors and by RUS. If standard forms were not used, borrowers would need to prepare their own documents at a significant expense; and each document submitted by a borrower would require extensive and costly review by both RUS and the Office of the General Counsel. Description of Respondents: Not-forprofit institutions; Business or other forprofit. Number of Respondents: 1,210. Frequency of Responses: Reporting: On occasion. Total Burden Hours: 104. Charlene Parker, Departmental Information Collection Clearance Officer. [FR Doc. E8–21907 Filed 9–18–08; 8:45 am] BILLING CODE 3410–15–P DEPARTMENT OF AGRICULTURE Animal and Plant Health Inspection Service jlentini on PROD1PC65 with NOTICES [Docket No. APHIS–2006–0188] Genetically Engineered Animals Animal and Plant Health Inspection Service, USDA. AGENCY: 17:25 Sep 18, 2008 Request for information. SUMMARY: The Animal and Plant Health Inspection Service (APHIS) is seeking public comment and scientific and technical empirical data and information concerning ongoing and future research on genetically engineered animals. APHIS’ interest is to ensure that genetically engineered animals imported into the United States or moved interstate do not present risks to U.S. livestock health. We also seek comment on what types of actions and approaches APHIS should consider in addressing any such risks that would complement the Food and Drug Administration’s (FDA’s) oversight, described in draft guidance elsewhere in this issue of the Federal Register. DATES: We will consider all comments that we receive on or before November 18, 2008. ADDRESSES: You may submit comments by either of the following methods: • Federal eRulemaking Portal: Go to https://www.regulations.gov/fdmspublic/ component/main?main=DocketDetail& d=APHIS–2006–0188 to submit or view comments and to view supporting and related materials available electronically. • Postal Mail/Commercial Delivery: Please send two copies of your comment to Docket No. APHIS–2006–0188, Regulatory Analysis and Development, PPD, APHIS, Station 3A–03.8, 4700 River Road Unit 118, Riverdale, MD 20737–1238. Please state that your comment refers to Docket No. APHIS– 2006–0188. Reading Room: You may read any comments that we receive on this docket in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue, SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690–2817 before coming. Other Information: Additional information about APHIS and its programs is available on the Internet at https://www.aphis.usda.gov. FOR FURTHER INFORMATION CONTACT: Biotechnology Regulatory Services, APHIS, 4700 River Road Unit 146, Riverdale, MD 20737–1236; 301–734– 5720. SUPPLEMENTARY INFORMATION: RIN 0579–AC37 VerDate Aug<31>2005 ACTION: Jkt 214001 Background In 1986, the Office of Science and Technology Policy (OSTP) under the Executive Office of the President PO 00000 Frm 00005 Fmt 4703 Sfmt 4703 published a policy document known as the Coordinated Framework for the Regulation of Biotechnology (the Coordinated Framework).1 This policy document describes the system for coordinating the activities of the Federal agencies responsible for regulating all GE organisms:2 The Environmental Protection Agency (EPA), the U.S. Department of Health and Human Services’ (HHS) Food and Drug Administration (FDA), and the U.S. Department of Agriculture (USDA), specifically the Animal and Plant Health Inspection Service (APHIS). The foundation of the Coordinated Framework is that existing health and safety laws administered by these Federal agencies provide a sound network of agency authorities for the regulation of GE organisms and products. Roles of APHIS and Other Agencies in the Regulation of GE Animals USDA and FDA both have authorities relevant to the oversight of GE animals. FDA has authority over new animal drugs under the Federal Food, Drug, and Cosmetic Act (FFDCA, 21 U.S.C. 321 et seq.). Elsewhere in the issue of the Federal Register, FDA is announcing the availability of draft guidance for public comment clarifying its oversight of GE animals under the new animal drug provisions of the FFDCA. The draft guidance explains that where a recombinant DNA construct in a GE animal is intended to affect the structure or function of the body of the GE animal, that construct is a new animal drug 3 regardless of the intended use of products that may be produced by the GE animal. The FFDCA requires that each new animal drug be approved through a new animal drug application (NADA) based on a demonstration that it is safe and effective for its intended use. FDA has been working with developers of GE animals for almost 20 years and the draft guidance is intended to clarify requirements and recommendations for producers and developers of GE animals and their products. 1 Coordinated Framework for the Regulation of Biotechnology: June 26, 1986; 51 FR 23302; https://usbiotechreg.nbii.gov/CoordinatedFramework ForRegulationOfBiotechnology1986.pdf. 2 In addition to discussing the regulatory responsibilities of these agencies for GE organisms and other products, the Coordinated Framework also discusses the responsibilities of agencies with jurisdiction over GE research (the National Institutes of Health, the National Science Foundation, EPA, and USDA’s Agricultural Research Service). 3 In accordance with the definition of ‘‘new animal drug’’ in 21 U.S.C. 321(v). E:\FR\FM\19SEN1.SGM 19SEN1 Federal Register / Vol. 73, No. 183 / Friday, September 19, 2008 / Notices The USDA has provided Federal leadership in protecting U.S. livestock health for more than 120 years. APHIS is authorized, under the Animal Health Protection Act (AHPA) (7 U.S.C. 8301 et seq.), to protect the health of U.S. livestock by preventing the introduction and spread of livestock diseases and pests into and within the United States. Based on that authority, APHIS may broadly consider the potential effects of animals with GE traits on the health of the overall U.S. livestock population, while FDA is more focused on the direct effects of genetic engineering on individual animals based on their authority under the FFDCA. Given these complementary authorities, APHIS and FDA have been discussing their respective roles in overseeing GE animals for some time. FDA’s release for public comment of its draft guidance on GE animals provides an excellent opportunity for APHIS to solicit public comment on the potential effects of animals with GE traits on U.S. livestock health. APHIS particularly seeks the following information: 1. What research on GE animals is currently being conducted or planned for the future? 2. What, if any, implications would activities such as the importation and interstate movement of such animals have for the health of the U.S. livestock population? 3. What, if any, activities should APHIS consider with respect to U.S. livestock health under the AHPA that would complement the requirements and recommendations described in FDA’s draft guidance? APHIS welcomes comments and scientific and technical information and data relevant to these issues. We will consider all comments and information we receive in determining the appropriate role for APHIS with regard to GE animals and will continue to collaborate closely with FDA. This action has been determined to be significant for the purposes of Executive Order 12866 and, therefore, has been reviewed by the Office of Management and Budget. jlentini on PROD1PC65 with NOTICES Authority: 7 U.S.C. 8301–8317; 7 CFR 2.22, 2.80, and 371. Done in Washington, DC, this 16th day of September 2008. Bruce Knight, Under Secretary for Marketing and Regulatory Programs. [FR Doc. E8–21977 Filed 9–18–08; 8:45 am] BILLING CODE 3410–34–P VerDate Aug<31>2005 17:25 Sep 18, 2008 Jkt 214001 DEPARTMENT OF AGRICULTURE Food Safety and Inspection Service [Docket No. FSIS–2008–0032] Codex Alimentarius Commission: 2nd Session of the Codex ad hoc Intergovernmental Task Force on Antimicrobial Resistance Office of the Under Secretary for Food Safety, USDA. ACTION: Notice of public meeting. AGENCY: SUMMARY: The Office of the Under Secretary for Food Safety, United States Department of Agriculture (USDA), and the Food and Drug Administration (FDA) are sponsoring a public meeting on September 25, 2008, to discuss the agenda items coming before the 2nd session of the Codex ad hoc Intergovernmental Task Force on Antimicrobial Resistance (AMR) and to present draft U.S. positions on the agenda items. The 2nd session of the AMR will be held in Seoul, Korea, October 20–24, 2008. The Under Secretary and FDA recognize the importance of providing interested parties the opportunity to comment on the agenda items that will be discussed at this forthcoming session of AMR. DATES: The public meeting is scheduled for Thursday, September 25, 2008, from 1 p.m. to 3 p.m. ADDRESSES: The public meeting will be held at FDA, 7519 Standish Place, Room 152, Rockville, MD. Documents related to the 2nd session of the AMR will be accessible via the World Wide Web at the following address: https:// www.codexalimentarius.net/ current.asp. For Further Information About the 2nd Session of the AMR Contact: U.S. Delegate, Dr. David White, Director, National Antimicrobial Resistance Monitoring System (NARMS), FDA, Center for Veterinary Medicine, Office of Research, 8401 Muirkirk Rd., Laurel, MD 20798, Phone: (301) 210–4181, E-mail: david.white@fda.hhs.gov. For Further Information About the Public Meeting Contact: Edith Kennard, Staff Officer, U.S. Codex Office, Food Safety and Inspection Service (FSIS), Room 4861, South Building, 1400 Independence Avenue, SW., Washington, DC 20250, Phone: (202) 720–5261, Fax: (202) 720–3157, E-mail: edith.kennard@fsis.usda.gov. SUPPLEMENTARY INFORMATION: Background The Codex Alimentarius (Codex) was established in 1963 by two United PO 00000 Frm 00006 Fmt 4703 Sfmt 4703 54361 Nations organizations, the Food and Agriculture Organization (FAO) and the World Health Organization (WHO). Through adoption of food standards, codes of practice, and other guidelines developed by its committees, and by promoting their adoption and implementation by governments, Codex seeks to protect the health of consumers and ensure that fair practices are used in trade. The Codex ad hoc Intergovernmental Task Force on AMR was established by the 29th Session of the Codex Alimentarius Commission in 2006 to develop science-based guidance to be used to assess the risks to human health associated with the presence in food and feed, including aquaculture, and the transmission through food and feed of antimicrobial resistant microorganisms and antimicrobial resistance genes. The AMR Task Force would also consider appropriate risk management options to reduce such risk. The Task Force is hosted by the Republic of Korea. Issues To Be Discussed at the Public Meeting The following items on the agenda for the 2nd session of the AMR will be discussed during the public meeting: • Matters Referred to the Committee from Other Codex Bodies • Information on the Work by FAO, WHO, and the World Organization for Animal Health on Antimicrobial Resistance • Proposed Draft Risk Assessment Guidance Regarding Foodborne Antimicrobial Resistant Microorganisms (Report of the Working Group) • Proposed Draft Guidance on Creating Risk Profiles for Antimicrobial Resistant Foodborne Microorganisms for Setting Risk Assessment and Management Priorities (Report of the Working Group) • Proposed Draft Risk Management Guidance to Contain Foodborne Antimicrobial Resistant Microorganisms (Report of the Working Group) Each issue listed will be fully described in documents distributed, or to be distributed, by the Korean Secretariat to the meeting. Members of the public may access copies of these documents at https:// www.codexalimentarius.net/ current.asp. Public Meeting At the September 25, 2008, public meeting, draft U.S. positions on these agenda items will be described and discussed, and attendees will have the opportunity to pose questions and offer comments. Written comments may be offered at the meeting or sent to the U.S. E:\FR\FM\19SEN1.SGM 19SEN1

Agencies

[Federal Register Volume 73, Number 183 (Friday, September 19, 2008)]
[Notices]
[Pages 54360-54361]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-21977]


-----------------------------------------------------------------------

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. APHIS-2006-0188]
RIN 0579-AC37


Genetically Engineered Animals

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Request for information.

-----------------------------------------------------------------------

SUMMARY: The Animal and Plant Health Inspection Service (APHIS) is 
seeking public comment and scientific and technical empirical data and 
information concerning ongoing and future research on genetically 
engineered animals. APHIS' interest is to ensure that genetically 
engineered animals imported into the United States or moved interstate 
do not present risks to U.S. livestock health. We also seek comment on 
what types of actions and approaches APHIS should consider in 
addressing any such risks that would complement the Food and Drug 
Administration's (FDA's) oversight, described in draft guidance 
elsewhere in this issue of the Federal Register.

DATES: We will consider all comments that we receive on or before 
November 18, 2008.

ADDRESSES: You may submit comments by either of the following methods:
     Federal eRulemaking Portal: Go to https://
www.regulations.gov/fdmspublic/component/
main?main=DocketDetail&d=APHIS-2006-0188 to submit or view comments and 
to view supporting and related materials available electronically.
     Postal Mail/Commercial Delivery: Please send two copies of 
your comment to Docket No. APHIS-2006-0188, Regulatory Analysis and 
Development, PPD, APHIS, Station 3A-03.8, 4700 River Road Unit 118, 
Riverdale, MD 20737-1238. Please state that your comment refers to 
Docket No. APHIS-2006-0188.
    Reading Room: You may read any comments that we receive on this 
docket in our reading room. The reading room is located in room 1141 of 
the USDA South Building, 14th Street and Independence Avenue, SW., 
Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., 
Monday through Friday, except holidays. To be sure someone is there to 
help you, please call (202) 690-2817 before coming.
    Other Information: Additional information about APHIS and its 
programs is available on the Internet at https://www.aphis.usda.gov.

FOR FURTHER INFORMATION CONTACT: Biotechnology Regulatory Services, 
APHIS, 4700 River Road Unit 146, Riverdale, MD 20737-1236; 301-734-
5720.

SUPPLEMENTARY INFORMATION:

Background

    In 1986, the Office of Science and Technology Policy (OSTP) under 
the Executive Office of the President published a policy document known 
as the Coordinated Framework for the Regulation of Biotechnology (the 
Coordinated Framework).\1\ This policy document describes the system 
for coordinating the activities of the Federal agencies responsible for 
regulating all GE organisms:\2\ The Environmental Protection Agency 
(EPA), the U.S. Department of Health and Human Services' (HHS) Food and 
Drug Administration (FDA), and the U.S. Department of Agriculture 
(USDA), specifically the Animal and Plant Health Inspection Service 
(APHIS). The foundation of the Coordinated Framework is that existing 
health and safety laws administered by these Federal agencies provide a 
sound network of agency authorities for the regulation of GE organisms 
and products.
---------------------------------------------------------------------------

    \1\ Coordinated Framework for the Regulation of Biotechnology: 
June 26, 1986; 51 FR 23302; https://usbiotechreg.nbii.gov/
CoordinatedFrameworkForRegulationOfBiotechnology1986.pdf.
    \2\ In addition to discussing the regulatory responsibilities of 
these agencies for GE organisms and other products, the Coordinated 
Framework also discusses the responsibilities of agencies with 
jurisdiction over GE research (the National Institutes of Health, 
the National Science Foundation, EPA, and USDA's Agricultural 
Research Service).
---------------------------------------------------------------------------

Roles of APHIS and Other Agencies in the Regulation of GE Animals

    USDA and FDA both have authorities relevant to the oversight of GE 
animals. FDA has authority over new animal drugs under the Federal 
Food, Drug, and Cosmetic Act (FFDCA, 21 U.S.C. 321 et seq.). Elsewhere 
in the issue of the Federal Register, FDA is announcing the 
availability of draft guidance for public comment clarifying its 
oversight of GE animals under the new animal drug provisions of the 
FFDCA. The draft guidance explains that where a recombinant DNA 
construct in a GE animal is intended to affect the structure or 
function of the body of the GE animal, that construct is a new animal 
drug \3\ regardless of the intended use of products that may be 
produced by the GE animal. The FFDCA requires that each new animal drug 
be approved through a new animal drug application (NADA) based on a 
demonstration that it is safe and effective for its intended use. FDA 
has been working with developers of GE animals for almost 20 years and 
the draft guidance is intended to clarify requirements and 
recommendations for producers and developers of GE animals and their 
products.
---------------------------------------------------------------------------

    \3\ In accordance with the definition of ``new animal drug'' in 
21 U.S.C. 321(v).

---------------------------------------------------------------------------

[[Page 54361]]

    The USDA has provided Federal leadership in protecting U.S. 
livestock health for more than 120 years. APHIS is authorized, under 
the Animal Health Protection Act (AHPA) (7 U.S.C. 8301 et seq.), to 
protect the health of U.S. livestock by preventing the introduction and 
spread of livestock diseases and pests into and within the United 
States. Based on that authority, APHIS may broadly consider the 
potential effects of animals with GE traits on the health of the 
overall U.S. livestock population, while FDA is more focused on the 
direct effects of genetic engineering on individual animals based on 
their authority under the FFDCA. Given these complementary authorities, 
APHIS and FDA have been discussing their respective roles in overseeing 
GE animals for some time. FDA's release for public comment of its draft 
guidance on GE animals provides an excellent opportunity for APHIS to 
solicit public comment on the potential effects of animals with GE 
traits on U.S. livestock health.
    APHIS particularly seeks the following information:
    1. What research on GE animals is currently being conducted or 
planned for the future?
    2. What, if any, implications would activities such as the 
importation and interstate movement of such animals have for the health 
of the U.S. livestock population?
    3. What, if any, activities should APHIS consider with respect to 
U.S. livestock health under the AHPA that would complement the 
requirements and recommendations described in FDA's draft guidance?
    APHIS welcomes comments and scientific and technical information 
and data relevant to these issues. We will consider all comments and 
information we receive in determining the appropriate role for APHIS 
with regard to GE animals and will continue to collaborate closely with 
FDA.
    This action has been determined to be significant for the purposes 
of Executive Order 12866 and, therefore, has been reviewed by the 
Office of Management and Budget.

    Authority: 7 U.S.C. 8301-8317; 7 CFR 2.22, 2.80, and 371.

    Done in Washington, DC, this 16th day of September 2008.
Bruce Knight,
Under Secretary for Marketing and Regulatory Programs.
[FR Doc. E8-21977 Filed 9-18-08; 8:45 am]
BILLING CODE 3410-34-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.